С

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

] 3	Check this box if no longer subject to Section 16. Form 4 or Form 5 biligations may continue. See nstruction 1(b).
-----	---

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

1. Name and Addres <u>Chodakewitz</u>	ss of Reporting Person Jeffrey	n*	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]	(Check	tionship of Reporting Person all applicable) Director Officer (give title	n(s) to Issuer 10% Owner Other (specify
INCORPORATE		(Middle) ALS	3. Date of Earliest Transaction (Month/Day/Year) 02/01/2018	X	below) EVP GMDA, C	below)
50 NORTHERN AVENUE (Street) BOSTON MA 02210 (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	idual or Joint/Group Filing (Form filed by One Report Form filed by More than C Person	ing Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

······································											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	02/01/2018		S ⁽¹⁾		1,900	D	\$167.44	52,524	D		
Common Stock	02/02/2018		М		1,796	A	\$91.05	54,320	D		
Common Stock	02/02/2018		S ⁽¹⁾		600	D	\$165.23(2)(3)	53,720	D		
Common Stock	02/02/2018		S ⁽¹⁾		996	D	\$166.1 ⁽³⁾⁽⁴⁾	52,724	D		
Common Stock	02/02/2018		S ⁽¹⁾		100	D	\$168.06	52,624	D		
Common Stock	02/02/2018		S ⁽¹⁾		100	D	\$169.49	52,524	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) (Disp of (I	rivative (Month/Day/Year) curities quired) or sposed (D) str. 3, 4			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$91.05	02/02/2018		М			1,796	(5)	02/01/2026	Common Stock	1,796	\$0.00	14,368	D	

Explanation of Responses:

1. Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.


2. Open market sales reported on this line occurred at a weighted average price of \$165.23 (range \$164.80 to \$165.67).

3. Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of \$166.10 (range \$165.81 to \$166.43).

5. The option vests in 16 quarterly installments from 2/2/2016.

Remarks:



Fact

02/05/2018

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.